AA
MRTX

AlphaCentric Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

AlphaCentric Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,000
Closed -$634K – 221
2022
Q4 		$634K Buy
+14,000
New +$906K 0.63% 59
2020
Q4 		– Sell
-80
Closed -$13K – 237
2020
Q3 		$13K Sell
80
-120
-60% -$16.4K 0.01% 153
2020
Q2 		$23K Buy
+200
New +$19.4K 0.01% 115

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AlphaCentric Advisors's MRTX Position: Q1 2023 in Review

AlphaCentric Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2023, closing a stake of 14,000 shares — an estimated $634K sold.

AlphaCentric Advisors first reported a position in MRTX in Q2 2020 and held it in 3 quarters. The position peaked at $634K in Q4 2022. 221 funds tracked by Wall St. Rank hold MRTX as of Q1 2023.

  • AlphaCentric Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • AlphaCentric Advisors sold 14,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $634K.
  • AlphaCentric Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • AlphaCentric Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $634K in Q4 2022.
  • 221 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2023.

Based on AlphaCentric Advisors's 13F filing for Q1 2023, filed 12 May 2023.